Stoke Therapeutics Builds Commercial Infrastructure as Clinical Catalysts Approach
Stoke Therapeutics is expanding market-access teams while two data readouts approach, but preparation is not proof of approval or commercial success.
Cocrystal Pharma’s Widening Loss Meets Fresh OPKO Backing and Norovirus Trial Progress
Nasdaq-listed COCP reported a wider $3.44 million quarterly loss alongside Phase 1b progress and a $5 million OPKO investment.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Norfolk Southern–Union Pacific Deal Spread Widens as CEO Remarks Stir Uncertainty
The widening spread between Norfolk Southern and Union Pacific puts deal timing and regulatory approval risk back in foc…
FTC Threat to Block $3.5 Billion Covetrus-MWI Deal Raises Stakes for M&A Traders
A reported FTC lawsuit over the $3.5 billion Covetrus-MWI deal highlights regulatory risk for merger arbitrage and healt…
Viking Therapeutics Takeover Chatter Puts VKTX Back in the M&A Spotlight
Renewed takeover interest lifted VKTX shares, sharpening the debate over obesity-drug consolidation and the risks of M&A…
October PPI Cools Slightly Against Expectations, Keeping Fed Rate Bets in Focus
October producer prices came in slightly below expectations, offering a nuanced signal for Federal Reserve policy watche…
FTC Challenge Puts $3.5 Billion Covetrus-MWI Deal in Doubt
A reported FTC plan to block Covetrus-MWI’s $3.5 billion merger raises deal-timing, completion-risk and consolidation co…
Sellas Life Sciences Surges 17% Ahead of Potentially Transformative AML Data
Sellas Life Sciences shares jumped 17% after hours as investors positioned for the company’s expected Phase 3 AML readou…
Candel Therapeutics Target Cut to $19 as BLA Delay Raises Regulatory Risk
Stifel cut Candel Therapeutics’ target to $19 after a BLA delay, while the biotech continues FDA discussions and readine…
Rezolute Stock Jumps 7.8% as Tumor Hypoglycemia Data Set Up FDA Catalyst
Rezolute shares rose 7.8% pre-market after tumor hypoglycemia data, with FDA discussions planned for Q1 2027 as topline …
Denali Therapeutics Gets Bullish Wells Fargo Initiation on Hunter Syndrome Drug
Wells Fargo initiated Denali Therapeutics at overweight, putting fresh sell-side attention on its approved Hunter Syndro…